{
    "medicine_id": "e121f376cb3fb2e798cc5d6f738fb30dbe10f829",
    "platform_id": "DB13881",
    "metadata": {
        "name": "Kymriah 2000000 1 1 Injection suspension",
        "composition": "2000000 1 1 Tisagenlecleucel",
        "clinical_particulars": {
            "therapeutic_indications": "Indicated for the treatment of patients up to 25 years of age with B cell precursor acute lymphoblastic leukemia ALL that is refractory or in second or later relapse FDA Label",
            "contraindications": {
                "disease": "Genotoxicity assay carcinogenicitiy assay and studies assesssing the effect of drug on fertility have not been conducted for tisagenlecleucel According to in vitro T cell expansion studies involving transduced T cells from healthy donors and patients there is no evidence of transformation and immortality FDA Label",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Tisagenlecleucel demonstrates efficacy in re inducing remission in patients with refractory B cell precursor acute lymphoblastic leukemia The sole purpose of the therapy is to eliminate CD19 expressing malignant and normal cells with specificity and increased chance of remission",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}